Home/Pipeline/ABD-0171

ABD-0171

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Advanced Biodesign

About Advanced Biodesign

Advanced BioDesign is a French biotech founded in 2010 with a mission to treat chemotherapy-resistant cancers by targeting the ALDH1 enzyme family, a key driver of tumor drug resistance and immunomodulation. The company has progressed its lead small-molecule inhibitor, ABD-3001, into clinical trials for AML and has a promising pre-clinical pipeline for solid tumors. Its integrated strategy combines therapeutic inhibitors with a companion diagnostic, ALDESCREEN®, aiming to personalize treatment and improve outcomes for patients with resistant cancers.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed